Novartis Taps Artios In Discovery Pact To Enhance Radioligand Portfolio
Wednesday, 7 April 2021, 13:08:04
Novartis AG (NYSE: NVS ) has struck a deal with UK-based Artios Pharma to access DNA damage response (DDR) targets that can potentially enhance its radioligand therapies. Artios is set to get $20 million upfront and up to $1.3 billion in milestones in return for the targets. During the three-year collaboration, Artios and Novartis will … Full story available on Benzinga.com
— Benzinga

Ark Funds, Illumina Invest In SomaLogic SPAC Deal: What Investors Should Know
Monday, 29 March 2021, 17:16:06
A leader in the proteomics field is going public with a SPAC deal announced Monday. The SPAC Deal: SomaLogic announced a SPAC deal with CM Life Sciences II Inc (NASDAQ: CMIIU ), valuing the company at $1.2 billion. A $375 million PIPE on the SPAC merger includes investments from SoftBank Group Corp (OTC: SFTBY ), T. Rowe Price, Illumina, Inc. (NASDAQ: ILMN ), Novartis AG (NYSE: NVS ) and accounts advised by Ark Invest. Kevin Conroy, the CEO of EXACT Sciences Corporation (NASDAQ: EXAS ) will join the board of directors after the merger is complete. Current shareholders of CM Life Sciences II will own 14% of the company after the merger. PIPE investors will own 20% of the company after the merger. About SomaLogic: Using … Full story available on Benzinga.com
— Benzinga

Wednesday, 24 March 2021, 16:30:28
https://www.investing.com/news/stock-market-news/novartis-corrects-chairmans-comments-about-kickbacks-case-2456087
— Investing.com

Novartis’ $2B cancer drug spurs ‘groundbreaking’ PhIII data for prostate cancer
Tuesday, 23 March 2021, 14:11:17
Continuing a streak of upbeat announcements on its radioligand portfolio, Novartis says that their Phase III study of 177Lu-PSMA-617 hit both co-primary endpoints on overall survival and radiographic progression-free survival for prostate cancer patients — setting up a likely approval some analysts believe would be worth more than a billion
— Endpoints News

Autoinjectors Market Is Expected To Exhibit 18.1% CAGR By 2027 | Novartis AG, SHL Medical, Eli Lilly and Company
Tuesday, 23 March 2021, 13:54:31
Rise in anaphylaxis cases and increases in R&D activities by key players in the market are anticipated to drive the market. Rapid growth has been observed in adoption of biosimilars over branded drugs, which provides low cost treatment options for
— OpenPR
We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.